Clinical Efficacy and Anatomical Basis for A Cavernosal Nerve Interposition Graft Douglas S. Scherr, M.D. Clinical Director, Urologic Oncology Weill Medical.

Slides:



Advertisements
Similar presentations
HELIOS Kliniken Leipziger Land Folie: 1 K. Kuhnt D. Schulz NESA DAYS 2006 Positive margins and early postop potency after Nerve-sparing ELRP Kai Kuhnt.
Advertisements

New Developments In The Management of Prostate Cancer
Is Radical Prostatectomy Adequate For High Risk Prostate Cancer?
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
NPCA data collection on men undergoing radical surgery for prostate cancer Paul Cathcart, NPCA Urology Project Coordinator.
Rising PSA after Radical Prostatectomy. My Approach. Dr Manish Patel Urological Cancer Surgeon Urological Cancer Surgeon Westmead Hospital University of.
Prostate Cancer Radical Prostatectomy
CA of Prostate:Incidence In a 50 y/o man In a 50 y/o man In autopsy: 40% In autopsy: 40% Clinical: 10% Clinical: 10% Death: 3% Death: 3% Most common non-cutanous.
Radical Prostatectomy: A Critical Analysis of Surgical Quality Between the Open and Laparoscopic Approaches. Karim Touijer, MD.
Management of T1 Kidney Cancer Laparoscopic Surgery
Prevention Strategies Rajesh G. Laungani MD Director, Robotic Urology Chairman, Prostate Cancer Center Saint Joseph’s Hospital, Atlanta.
Role of MRI and MRSI in The Management of Prostate Cancer Karim Touijer, MD.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Mr Jonathan Lewin MBBS, MRCS, MD, FRCS(Urol), FRACS Consultant Uro-Oncological Surgeon.
PROSTATE CANCER EXPECTED MANAGEMENT & CURATIVE TREATMENT Dr. Abdullah A. Ghazi (R5) KSMC.
NEW OPTIONS IN PROSTATE CANCER TREATMENT Presented by Triangle Urology Associates, P.A.
Steven Joniau Filip Ameye
Prostate Cancer Symposium An Educational Initiative For Patients, Spouses, Advocates and Healthcare Professionals Restoring Quality of Life: Managing Side-effects/Pain.
1 NDA / S012 CASODEX (bicalutamide) 150 mg FDA Review Division of Reproductive and Urologic Drug Products (DRUDP)
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Prostate Cryotherapy Minimally Invasive Cancer Treatment PM-3590 Rev A 08/11 This information is intended for general patient education purposes only in.
Surgical Management of Urothelial Carcinoma A 21 st Century Approach Douglas S. Scherr, M.D. Clinical Director, Urologic Oncology Weill Medical College.
Prof Stephen Langley Professor of Urology St Luke’s Cancer Centre, Guildford, UK PGMS, University of Surrey Focal Brachytherapy UK experience.
Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Prostate VTP: Clinical Trial Update
T4 Colon Cancer and Laparoscopic Approach Gustavo Plasencia MD FACS, FASCRS Clinical Professor of Surgery Gustavo Plasencia MD FACS, FASCRS Clinical Professor.
Douglas S. Scherr, M.D. Assistant Professor of Urology
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
What is the Preferable Treatment Option for T1/T2 Low Rectal Cancer? Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology.
Prostate Cancer Treatment: What’s Best For You?
Prevention with Finasteride Ian M. Thompson, MD October, 2009.
Urinary Diversion: Does RARC learning curve affect diversion choice in urothelial carcinoma PG O’Malley 1, B Al Hussein Al Awamlh 1, DP Nguyen 1, BM Faltas.
POTENTIAL FOR FAILURE OF FOCAL PROSTATE HEMI-ABLATION STRATEGIES PG O’Malley 1, B Al Hussein Al Awamlh 1, AM Sarkisian 1, DP Nguyen 1, S Jin 1, R Lee 1,
Laparoscopic Radical Prostatectomy: Oncological and Functional Outcomes Following Fellowship Training. Introduction Radical Prostatectomy (RP) is a technically.
Robert Dreicer, M.D., M.S., FACP Chair Dept of Solid Tumor Oncology
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Introducing a new and simple scoring system to evaluate oncological and functional outcome after radical prostatectomy Salomon L., De La Taille A., Vordos.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
Prostate Cancer Screening Risk Management Ben Inch.
The GOLIATH Study ..
MpMRI in Prostate cancer A Urologist’s Perspective Diagnosis Treatment Choice Surgical Planning Dr. Peter Heathcote, Adjunct Professor APCRC-Q QUT, Senior.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Minimally Invasive Approaches in the Treatment of Urothelial Carcinoma “Robotic Radical Cystectomy” Douglas S. Scherr, M.D. Weill Medical College of Cornell.
Mamoun A. Rahman Surgical SHO Mr Osborne’s team. Introduction Blood transfusion: -Preoperative ( elective) -Intra/postoperative ( urgent) Blood transfusion.
Understanding Prostate Myths
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Operative Management of Osteosarcoma Patients with Pulmonary Metastasis Jen Kramer, MD R2 Swedish Medical Center February 2011.
Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.
Debra Freeman, MD – Naples Christopher King, MD, PhD - Stanford.
David Spellberg, M.D., FACS Naples Urology Associates, P.A.
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
IN THE NAME OF GOD. What are Stem Cells? Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types.
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.
Robotic Surgery for Prostate Cancer: A Realistic Approach to Getting Started “The Evolution of a Robotic Surgeon” Douglas S. Scherr, M.D. Clinical Director,
Robotic-assisted Laparoscopic Prostatectomy
Disfunzione erettile dopo prostatectomia radicale
Radiation therapy for Early Stage Prostate Cancer
Surgical Treatment in Locally Advanced Prostate Cancer
Prevention of Prostate Cancer. Fact or Fiction?
Robotic Radical Prostatectomy. Anatomic Considerations
New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.
Laparoscopic Radical prostatectomy: Is it still a treament of choice?
Volume 13, Issue 6, Pages (June 2012)
ROBOTIC ASSISSTED RADICAL PROSTATECTOMY OUR INITIAL EXPERIENCE
Apollo Gleneagles Hospitals,
Erectile dysfunction and Penile rehabilitation following radical prostatectomy 김 세 웅 여의도성모병원비뇨기과.
Adjuvant Radiation is Required for Gastric Cancer
Volume 13, Issue 6, Pages (June 2012)
Presentation transcript:

Clinical Efficacy and Anatomical Basis for A Cavernosal Nerve Interposition Graft Douglas S. Scherr, M.D. Clinical Director, Urologic Oncology Weill Medical College of Cornell University

Background Significant stage migration: cT3:25% in % in % of men with cT3 treated with XRT will recur locally 20-30% of cT3 treated with RRP will have organ confined disease Carver et al. J Urol, 176, , 2006

Effectiveness of RRP in cT3 Disease XRT as monotherapy 10-20% 5 year bDFS XRT +Hormones: 74% bDFS (Bolla et al.) RRP for cT3 Disease -Mayo series: 90% 10yr CSS (52% received adjuvant hormones) -MSKCC series: 44% 10 yr bDFS 85% CSS at 10 years (no adjuvant tx) Local recurrence rates after XRT 20-60% Carver et al. J Urol, 176: , 2006

Background RRP has a clear role in cT3 disease Resection of NVB may be indicated DRE, PSA, Endorectal MRI, site specific label of biopsy information Effect on Erectile function

Effect of Neurovascular Bundle Resection Rabbani et al. J Urol, , 2000 Age Preop Erectile Status Extent of NVB Preservation

Effect of Bilateral Resection Borchers et al. Urol Int, 76: , 2006

What can be Done? Penile Injection therapy Vacuum Erection Devices Surgical Implant Devices Nerve Grafting?

Anatomical Basis for Nerve Grafting Walsh and Donker 1982 One single nerve vs. network of nerve bundles Variation in anatomic location

History of Cavernosal Nerve Graft Quinlan and Walsh demonstrate efficacy of cavernosal nerve graft in rat model Walsh 2000 expresses skepticism 2000 – Kim et al. report on first experience in 2 patients with bilateral grafts with recovery of complete erectile function

Role of a Nerve Graft Serves as conduit for nerve regeneration Source of Schwann cells and growth factors

Published Results of Cavernosal Nerve Grafting AuthorCenter# patients Mean Age Unilateral vs. Bilateral Potency Rate (Unassited) Potency rate with Medication Mean Follow up (mos) Graft UsedComment Kim et al.Baylor/MSKCC2359Bilateral6/23(26%)10/23(43%)23Sural Perotte et al.MD Anderson/Univ. of Montreal 8Bilateral3/8 (37.5%)12Sural Masterson et al. MSKCC11Unilateral0%SuralSalvage RRP Anastasiadis et al. Columbia1257.5Unilateral4/12(33%)16.1Sural Nelson et al.Vanderbilt275719% bi 81% uni 4/27(15%)10/27(37%)14Genitofemoral Porpiglia et al Univ. of Turin, Italy 1266Unilateral5/12(42%)18.4SuralLaparoscopic

Role of Nerve Graft in Continence? Singh et al – 53pts with unilateral nerve graft Compared unilat. Nerve resection with and without graft UCLA Prostate Cancer Index Questionnaire Multivariate analysis showed that UNR+SNG associated with 9.95 times greater chance of reaching complete urinary control Contribution of cavernosal nerve to external sphincter function Singh et al. Urology, 63(6): , 2004

PatientAgePreop PSA Clincal Stage Initial Gleason Final Gleason P StageMargin Status HormonesUnilateral vs. Bilateral Unassiste d Potency Potent with Medication T2A77T2BN0M0NegativeNoneUnilateralNo 26036T3B89T3AN1M0NegativeYesBilateralNo T1C99T3AN0M0PositiveYesBilateralNo 44921T2B67T3AN0M0NegativeNoneUnilateralYes T1C66T2BN0M0NegativeNoneUnilateralNoYes T2B77T3AN0M0NegativeNoneUnilateralNoYes Robotic Genitofemoral-Cavernosal Nerve Graft Experience Weill Medical College of Cornell University Mean Follow up 14.1 months

Technique of Robotic Nerve Graft Robotic RRP performed in standard fashion Proximal and distal end of nerve identified and marked with suture (Cavermap assisted) NVB resected en bloc with prostate Graft site measured for length – 20% longer than required Genitofemoral nerve harvested and retrieved Reverse graft placed with 7.0 sutures Urethrovesical anastamosis performed

Conclusion Early data on nerve grafting is intriguing Robotic nerve grafting is feasible May have some benefit in urinary function Multicenter, randomized trials are necessary to validate results